| |
September 8-11, 2025 | Philadelphia, PA Join the industry's top minds at Fierce Pharma Week—where innovation, strategy, and partnerships converge. Don’t miss your chance to lead the future of pharma. Register Today.
|
|
Today’s Big NewsJun 30, 2025 |
|
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now.
|
|
| By Nick Paul Taylor AbbVie is making a full strength play for the in vivo CAR-T market, snapping up Capstan Therapeutics for $2.1 billion to add an early-phase autoimmune drug candidate to its pipeline. |
|
|
|
By Gabrielle Masson Amgen’s investigational monoclonal antibody paired with chemotherapy significantly improved overall survival for patients in a phase 3 stomach cancer trial compared to chemotherapy alone, according to the pharma. |
By Nick Paul Taylor A phase 2 study of INmune Bio’s TNF inhibitor in Alzheimer’s disease has missed its primary endpoint, wiping 60% off the biotech share price. |
Sponsored by Invest Puerto Rico With decades of excellence in biosciences, Invest PR’s CEO shares how the island is uniquely positioned to lead the reshoring movement. |
|
Discover how flow chemistry can revolutionize your chemical processes and position your business for long-term success. This insightful whitepaper explores how flow chemistry is transforming pharmaceutical manufacturing, significantly reducing waste and energy consumption. Download now.
|
|
By James Waldron The long and winding journey of Moderna’s mRNA flu vaccine toward regulators has come one step closer with a phase 3 win over an approved competitor candidate. |
By James Waldron Pfizer has added another chapter to its long-running drug discovery collaboration with Chinese tech startup XtalPi, this time upgrading their molecular modeling work. |
By James Waldron Pliant Therapeutics has terminated its idiopathic pulmonary fibrosis (IPF) program after digging into the increased rate of adverse events from a 2b/3 trial of its lead candidate bexotegrast. |
By Kevin Dunleavy Two weeks after Supernus Pharmaceuticals unveiled the proposed acquisition of Sage Therapeutics, all 338 employees from the latter company are being laid off, according to a Massachusetts Worker Adjustment and Retraining Notification. |
By Angus Liu The FDA has removed the REMS requirements for currently approved BCMA- and CD19-directed CAR-T therapies and reduced certain post-infusion restrictions. |
By Angus Liu The Orphan Cures Act has been added back into the Senate version of President Donald Trump's “big, beautiful bill” after being left out in the chamber’s first rendition. |
By Andrea Park,Nick Paul Taylor,Zoey Becker The top 10 meds were responsible for about a third of all pharmaceutical advertising spending in 2024; MediaRadar reported more than $10.1 billion spent marketing all prescription drugs last year, a year-over-year increase of about 2%. |
By Conor Hale Glaukos said the approvals were its first under the European Union’s new and more-stringent Medical Device Regulation pathway. |
By Dave Muoio The largely blue state legal officers said the government's rescindment of guidance on stabilizing abortion care does not change the requirements laid out in federal statute—the precise interpretation of which is still being hashed out in courts. |
Fierce podcastsDon’t miss an episode |
| | In this episode of "The Top Line," Teva CEO Richard Francis shares progress on the company’s “Pivot to Growth” strategy and what lies ahead. |
|
|---|
|
|
|
Now Available On-Demand Access this deep dive to gain valuable insights and guidance from leading industry experts on diagnostic and precision medicine testing. Register now.
|
|
| Whitepaper Presented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
| Executive SummaryBiotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster. Sponsored by: IQVIA Laboratories |
| WhitepaperWe analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
